Petrescu A, Cajal N, Broniţki A, Mihail A, Teodosiu O, Popescu G, Isaia G, Popescu A
Virologie. 1977 Jul-Sep;28(3):213-7.
Studies conducted for over 20 years allowed the authors to accumulate a rich experience in the production and administration of an inactivated influenza vaccine applicable by nasal and oral route, prepared in the "Stefan S. Nicolau" Institute of Virology. Applied as a monovalent in a single dose of 1000 IU, the vaccine induced seroconversion of 70% of the vaccines and ensured a 2--4-fold decrease in influenza morbidity. Owing to these qualities the vaccine represents one of the most advantageous preparations used in influenza prophylaxis.
20多年来开展的研究使作者们在生产和管理一种可通过鼻内和口服途径接种的灭活流感疫苗方面积累了丰富经验,该疫苗由“斯特凡·S·尼科劳”病毒学研究所制备。作为单价疫苗以1000国际单位的单剂量使用时,该疫苗使70%的接种者产生了血清转化,并确保流感发病率降低了2至4倍。由于这些特性,该疫苗是用于流感预防的最具优势的制剂之一。